Ipsen SA
Company Profile
Business description
Ipsen is a global biotechnology company headquartered in France that develops and commercializes medicines across three therapeutic areas: oncology, neuroscience, and rare diseases. Ipsen was founded in 1929 as a consumer healthcare company focused on prescription-based products for digestive disorders and neurological disorders. Over the past nearly 100 years, Ipsen has shifted its focus to specialty care, which comprises the vast majority of its total revenue. In February 2022, Ipsen announced the divestment of its consumer healthcare business, which accounted for 8% of 2021 revenue. Ipsen has a large global footprint and sells more than 25 drugs in 115 countries.
Contact
70 rue Balard
Paris75015
FRAT: +33 158335000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
5,358
Stocks News & Analysis
stocks
Qantas earnings: Jetstar capitalising on weaker domestic competition
stocks
Nvidia Earnings: No signs of a slowdown in demand for AI chips
stocks
ASX results reaction: WiseTech, Woolies, Sigma and more
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,188.00 | 29.40 | -0.32% |
| CAC 40 | 7,703.90 | 58.70 | -0.76% |
| DAX 40 | 23,902.21 | 137.71 | -0.57% |
| Dow JONES (US) | 45,544.88 | 92.02 | -0.20% |
| FTSE 100 | 9,187.34 | 29.48 | -0.32% |
| HKSE | 25,611.40 | 533.78 | 2.13% |
| NASDAQ | 21,455.55 | 249.61 | -1.15% |
| Nikkei 225 | 41,849.82 | 868.65 | -2.03% |
| NZX 50 Index | 13,000.11 | 69.38 | 0.54% |
| S&P 500 | 6,460.26 | 41.60 | -0.64% |
| S&P/ASX 200 | 8,920.00 | 28.80 | -0.32% |
| SSE Composite Index | 3,871.58 | 13.65 | 0.35% |